AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for children aged six and older living with moderate-to-severe plaque...
AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZTM (pivekimab sunirine-pvzy), first and only antibody-drug conjugate (ADC) drug for the treatment of Blastic Plasmacytoid Dendritic Cell...